Literature DB >> 3095989

Fetomaternal transplacental hemorrhage during pregnancy and after delivery.

J M Bowman, J M Pollock, L E Penston.   

Abstract

One third of very weakly Rh-immunized women show no increase in their level of Rh immunization during pregnancy and after delivery. Administration of 300 micrograms of Rh immune globulin at 6-week intervals does not alter the incidence of lack of progression of Rh immunization in such women. Thirty-three Rh-positive women who ultimately delivered ABO-compatible babies, had Kleihauer fetal transplacental hemorrhage (TPH) screening tests carried out at 2-week intervals during pregnancy and shortly after delivery. One third of the 33 women had no detectable TPH or a TPH of 0.01 ml of fetal red cells. We conclude that one third of weakly Rh-immunized women failed to show any progression of their Rh immune response during pregnancy or after delivery because they were exposed to too few fetal red cells (0.01 ml or less) to produce such a response.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095989     DOI: 10.1111/j.1423-0410.1986.tb00226.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  16 in total

1.  Management of pregnancies with RhD alloimmunisation.

Authors:  Sailesh Kumar; Fiona Regan
Journal:  BMJ       Date:  2005-05-28

2.  The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.

Authors:  Conglei Li; Siavash Piran; Pingguo Chen; Sean Lang; Alessandro Zarpellon; Joseph W Jin; Guangheng Zhu; Adili Reheman; Dianne E van der Wal; Elisa K Simpson; Ran Ni; Peter L Gross; Jerry Ware; Zaverio M Ruggeri; John Freedman; Heyu Ni
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 3.  The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Authors:  Giancarlo Maria Liumbruno; Angelo D'Alessandro; Federica Rea; Vanessa Piccinini; Liviana Catalano; Gabriele Calizzani; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

4.  Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Authors:  Francesco Bennardello; Serelina Coluzzi; Giuseppe Curciarello; Tullia Todros; Stefania Villa
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

5.  Demographics, clinical characteristics and outcomes of neonates diagnosed with fetomaternal haemorrhage.

Authors:  Annemarie Stroustrup; Leonardo Trasande
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-02-28       Impact factor: 5.747

Review 6.  Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-11-02

Review 7.  Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn.

Authors:  Morten Hanefeld Dziegiel; Grethe Risum Krog; Anne Todsen Hansen; Marianne Olsen; Birgitte Lausen; Lone Nikoline Nørgaard; Thomas Bergholt; Klaus Rieneck; Frederik Banch Clausen
Journal:  Transfus Med Hemother       Date:  2021-09-08       Impact factor: 3.747

8.  Impact of physician awareness on diagnosis of fetomaternal hemorrhage.

Authors:  Annemarie Stroustrup; Callie Plafkin; David A Savitz
Journal:  Neonatology       Date:  2014-02-08       Impact factor: 4.035

9.  Does Rh immune globulin suppress HLA sensitization in pregnancy?

Authors:  Richard M Kaufman; Karen S Schlumpf; David J Wright; Darrell J Triulzi
Journal:  Transfusion       Date:  2012-12-17       Impact factor: 3.157

Review 10.  Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.

Authors:  B M Kumpel
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.